These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26186809)

  • 1. Evaluating the Cost of Bringing People with Type 2 Diabetes Mellitus to Multiple Targets of Treatment in Canada.
    Skovgaard R; Jon Ploug U; Hunt B; Valentine WJ
    Clin Ther; 2015 Aug; 37(8):1677-88. PubMed ID: 26186809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
    Langer J; Hunt B; Valentine WJ
    J Manag Care Pharm; 2013 Apr; 19(3):237-46. PubMed ID: 23537458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States.
    Hunt B; McConnachie CC; Gamble C; Dang-Tan T
    J Med Econ; 2017 Nov; 20(11):1117-1120. PubMed ID: 28651479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
    Johansen P; Sandberg A; Capehorn M
    Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
    Hunt B; Hansen BB; Ericsson Å; Kallenbach K; Ali SN; Dang-Tan T; Malkin SJP; Valentine WJ
    Adv Ther; 2019 Dec; 36(12):3483-3493. PubMed ID: 31650514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Lee WC; Conner C; Hammer M
    Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.
    Zinman B; Schmidt WE; Moses A; Lund N; Gough S
    Diabetes Obes Metab; 2012 Jan; 14(1):77-82. PubMed ID: 21883806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
    Dempsey M; Mocarski M; Langer J; Hunt B
    Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide vs. sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: Short-term cost-per-controlled patient in Italy.
    Ferrario MG; Lizán L; Montagnoli R; Ramírez de Arellano A
    Prim Care Diabetes; 2016 Jun; 10(3):220-6. PubMed ID: 26546244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.
    Hunt B; Mocarski M; Valentine WJ; Langer J
    Adv Ther; 2017 Apr; 34(4):954-965. PubMed ID: 28281218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide for the treatment of type 2 diabetes.
    Shyangdan D; Cummins E; Royle P; Waugh N
    Health Technol Assess; 2011 May; 15 Suppl 1():77-86. PubMed ID: 21609656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
    Hunt B; Mocarski M; Valentine WJ; Langer J
    J Med Econ; 2017 Jul; 20(7):663-670. PubMed ID: 28294641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
    Kirkman MS; Tripputi M; Krause-Steinrauf H; Bebu I; AbouAssi H; Burch H; Duran-Valdez E; Florez H; Garvey WT; Hsia DS; Salam M; Pop-Busui R;
    Diabetes Care; 2024 Apr; 47(4):594-602. PubMed ID: 38194519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
    Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
    Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost effectiveness of liraglutide in type II diabetes: a systematic review.
    Zueger PM; Schultz NM; Lee TA
    Pharmacoeconomics; 2014 Nov; 32(11):1079-91. PubMed ID: 25052903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
    Tunis SL; Sauriol L; Minshall ME
    Appl Health Econ Health Policy; 2010; 8(4):267-80. PubMed ID: 20578781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
    Davies MJ; Chubb BD; Smith IC; Valentine WJ
    Diabet Med; 2012 Mar; 29(3):313-20. PubMed ID: 21883438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.